


01-09-02

1040 U.S. PTO
01/07/02Please type a plus sign (+) inside this box → ☐1040 U.S. PTO
10/04/006

01/07/02

UTILITY PATENT APPLICATION TRANSMITTAL <small>(only for new non-provisional applications under 37 CFR 1.53(b))</small>		Attorney Docket No. ORT-1565	
		First Named Inventor or Application Identifier	
		DARROW, Andrew L.	
		Express Mail No.	EU014011286US
APPLICATION ELEMENTS See MPEP Chapter 600 concerning utility patent application contents.		ADDRESS TO: Assistant Commissioner for Patents BOX PATENT APPLICATION Washington, DC 20231	
1. <input checked="" type="checkbox"/> Fee Transmittal Form (attached hereto in duplicate) 2. <input checked="" type="checkbox"/> Specification [Total Pages: 69] 3. <input checked="" type="checkbox"/> Drawing(s) (35 USC 113) [Total Sheets: 6] 4. Oath or Declaration: A copy from a prior application is attached hereto (37 CFR 1.63(d)). 5. Nucleotide and/or Amino Acid Sequence Submission (if applicable, all necessary) a. <input checked="" type="checkbox"/> Computer Readable Copy b. <input checked="" type="checkbox"/> Paper Copy (identical to computer copy) c. <input checked="" type="checkbox"/> Statement verifying identity of above copies		6. <input checked="" type="checkbox"/> Information Disclosure Statement (IDS)/PTO-1449 7. <input checked="" type="checkbox"/> Preliminary Amendment 8. <input checked="" type="checkbox"/> Return Receipt Postcard (MPEP 503) (Should be specifically itemized) 9. <input checked="" type="checkbox"/> Other: Express Mail Certification	
10. <input type="checkbox"/> Incorporation by Reference (useable if Box 4c is checked) The entire disclosure of the prior application, from which a copy of the oath or declaration is supplied under Box 4c, is considered as being part of the disclosure of the accompanying application and is hereby incorporated by reference therein.			
PRELIMINARY AMENDMENT			
11. Please amend the specification by inserting before the first line: This is a <i>Divisional</i> of prior application No.: <u>09/386,653</u> , filed <u>31 August 1999</u> .			
12. Please cancel original Claims <u>1-16</u> and <u>21-27</u> of the prior application before calculating the filing fee.			
13. Correspondence Address: Name: <u>Philip S. Johnson, Esq.</u> Address: <u>Johnson & Johnson</u> <u>One Johnson & Johnson Plaza</u> <u>New Brunswick, NJ 08933-7003, USA</u>			
14. Telephone Contact: Please direct all telephone calls or tele-faxes to John W. Wallen, III at: Telephone: (858) 784-3239 Fax: (732) 524-2808			
SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT REQUIRED			
NAME	John W. Wallen, III, Esq. Reg. No. 35,403		
SIGNATURE		DATE	7 January 2002

1040 U.S. PTO
01/07/02


FEE TRANSMITTAL	Complete if Known	
	Application Number	NOT ASSIGNED
	Filing Date	7 January 2002
	First Named Inventor	DARROW
	Group Art Unit	1652
	Examiner Name	MOORE, W.
	Attorney Docket Number	ORT-1565

FEE CALCULATION**CLAIMS AS FILED**

(1)	(2)	(3)	(4)	(5)
FOR:	NUMBER FILED	NUMBER EXTRA	RATE	BASIC FEE (\$710.00)
TOTAL CLAIMS	4 - 20 =	0	x 18.00	\$ 0.00
INDEPENDENT CLAIMS	2 - 3 =	0	x 80.00	\$ 0.00
MULTIPLE DEPENDENT CLAIMS	<input type="checkbox"/>	N/A	\$270.00	
			TOTAL FEES	\$710.00

METHOD OF PAYMENT

- ☒ Please charge Deposit Account No. 10-0750/ORT-1565/JWW in the amount of \$710.00. Three copies of this sheet are enclosed.
- ☒ The Commissioner is hereby authorized to charge any additional fees which may be required in connection with the filing of this communication, or credit any overpayment, to Account No. 10-0750/ORT-1565/JWW. Three copies of this sheet are enclosed.

SUBMITTED BY:		Complete (if applicable)
Typed or Printed Name	John W. Wallen, III	Reg. No. 35,403
Signature		Deposit Account No. 10-0750
	Date: 7 Jan. 2002	

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Andrew L. DARROW, Jenson QI and Patricia ANDRADE-GORDON

Serial No.: N/A Art Unit: 1652

Filed: 7 January 2002 Examiner: MOORE, W.

For: DNA ENCODING THE HUMAN SERINE PROTEASE T

Assistant Commissioner for Patents
BOX: Patent Applications
Washington, D.C. 20231

**REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING
NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES**

Sir:

Submitted herewith is a computer readable form of the Sequence Listing with the appropriate statements that the computer readable and paper copies are the same.

The following statements are made as required by 37 C.F.R. 1.821(f): I hereby state that the information recorded in computer readable form of the Sequence Listing is identical to the written sequence listing.

Respectfully submitted,


John W. Wallen, III

Reg. No. 35,403

Attorney for Applicant(s)

Johnson & Johnson
One Johnson & Johnson Plaza
New Brunswick, NJ 08933-7003
(858) 784-3239

DATE: 7 January 2002

20201010 010000